drugset
drugset / Trial / NCT04553978

A Single Oral Dose, Crossover Comparative PK Study of WD-1603 in Healthy Subjects Under Fasting Conditions

NCT04553978 ↗

Phase 1 Unknown 8 enrolled Hong Kong WD Pharmaceutical Co., Limited
RandomizedCrossoverOpen-labelTreatment

Summary

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single oral dose, crossover comparative Pharmacokinetics study of WD-1603 extended-release carbidopa/levodopa tablets in normal, healthy, adult human subjects under fasting conditions

Timeline

Start
2020-09-18
Primary completion
2021-03-18
Completion
2021-03-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbidopa Unknown — Oral
Subject Levodopa Small molecule — Oral

Indications

Parkinson disease